March 31, 2020
Johnson & Johnson (JNJ) has selected a lead COVID-19 vaccine candidate and two back-ups from constructs it has been working on since this past January, when the virus began emerging as a global threat. The New Brunswick, NJ-based pharmaceutical giant plans a rapid scaling of its manufacturing capacity, with the goal of providing global supply of more than one billion doses of a vaccine.
“We are moving on an accelerated timeline toward Phase 1 human clinical trials at the latest by September 2020, and, supported by the global production capability that we are scaling up in parallel to this testing, we expect a vaccine could be ready for emergency use in early 2021,” said Paul Stoffels, chief scientific officer, JNJ.
For comparison, JNJ says, the typical vaccine development process involves a number of different research stages, spanning five to seven years, before a candidate is even considered for approval.
Pictured: A researcher at Janssen Labs in the Netherlands, part of JNJ’s research team on a COVID-19 vaccine.
For comments, questions or concerns, please contact Paul Bubny